Showing 3511-3520 of 7027 results for "".
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://practicaldermatology.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://practicaldermatology.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Bullous Pemphigoid: The Time to Treat Is Now, Fall Clinical Speakers Sayhttps://practicaldermatology.com/news/bullous-pemphigoid-the-time-to-treat-is-now-fall-clinical-speakers-say/2484090/Earlier recognition of bullous pemphigoid (BP) is critical but safer, targeted treatment options are emerging for this aging and medically fragile patient population, according to a presentation from Donna Culton, MD, PhD, and Prince Adotama, MD, at the 2025 Fall Clinical Dermatology Conference.<
- Long-Term Baricitinib Data Reinforce Potential in Adolescents With AAhttps://practicaldermatology.com/news/long-term-baricitinib-data-reinforce-potential-in-adolescents-with-aa/2484088/More than half of adolescents treated for alopecia areata (AA) with baricitinib 4mg achieved successful scalp hair response by Week 52, with a response rate reaching 71% among those with baseline Severity of Alopecia Tool (SALT) score of 50-94, according to new data presented at the 2025 Fall Cli
- Global CME Conference to Spotlight Eczema Burden, Treatment Advanceshttps://practicaldermatology.com/news/global-cme-conference-to-spotlight-eczema-burden-treatment-advances/2483912/Health & Wellness Global Alliance will host its inaugural H&W Global Dermatology CME Conference November 12-16, 2025, aiming to spotlight the international burden of eczematous diseases. The event aligns with the mission
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://practicaldermatology.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia
- Analysis: Dupilumab-Related Adverse Events Less Common in Black Adults With ADhttps://practicaldermatology.com/news/analysis-dupilumab-related-adverse-events-less-common-in-black-adults-with-ad/2483504/A retrospective chart review in the Journal of Drugs in Dermatology yielded insights into dupilumab-associated adverse events (d-AEs) in Black and African American (AA) adults treated for atopic dermatitis (AD). The st
- From EADV: Bimekizumab Shows Sustained Efficacy in Plaque Psoriasis and HShttps://practicaldermatology.com/news/from-eadv-bimekizumab-shows-sustained-efficacy-in-plaque-psoriasis-and-hs/2483464/New data presented by UCB at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris showed sustained efficacy and tolerability for BIMZELX® (bimekizumab-bkzx) in both moderate-to-severe hidradenitis suppurativa (HS) and plaque psoriasis. <
- ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Awardhttps://practicaldermatology.com/news/zoryve-wins-2025-allure-best-of-beauty-breakthrough-award/2483410/Arcutis Biotherapeutics’ ZORYVE® (roflumilast) was the recipient of Allure magazine’s 2025 Best of Beauty Breakthrough Award, marking the first time a prescription topical for atopic dermatitis (AD), plaque psoriasis, and seborrheic dermatitis has received the accol